"Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly and Company executive vice-president and Lilly International president Ilya Yuffa stated: "It is exciting to see Kisunla's marketing authorisation in Australia, marking it as the 13th ...

Eli Lilly has spent recent years reintroducing itself to the public via a series of corporate campaigns, and its latest push goes a step further.

Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

The Lilly-Purdue 360 announcement on Friday (May 9) achieved significant media attention. Purdue and Eli Lilly announced an expansion of their long-standing academic agreement with Lilly’s planned… ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Marketing Lilly enlists ‘Modern Family’ star for musical Mounjaro campaign By Andrea Park May 2, 2025 2:34pm Eli Lilly Mounjaro Type 2 diabetes celebrity spokespeople ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance, with Lilly’s ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.